Danaher Q2 Earnings Beat, Raises Full-Year EPS Guidance

summarizeSummary

Danaher reported Q2 2026 earnings above expectations, with net earnings up 60% to $870 million and adjusted EPS of $1.94. The company raised its full-year adjusted EPS guidance and provided a positive outlook, driven by improving end markets and strong bioprocessing orders.

check_boxKey Events · Earnings and Guidance · DHR

• Q2 Earnings Beat

  Net earnings of $870 million ($1.23 diluted EPS), up 60% year-over-year. Non-GAAP adjusted diluted EPS of $1.94, up 8.0%.

• Revenue Growth Accelerates

  Revenue of $6.3 billion, up 5.5% year-over-year. Core revenue growth of 3.0%, with Life Sciences delivering its strongest quarter in several years.

• Full-Year EPS Guidance Raised

  Adjusted diluted EPS guidance increased to $8.45–$8.60 from $8.35–$8.55, reflecting confidence in continued recovery and Masimo integration.

• Bioprocessing Orders Surge

  Bioprocessing orders grew mid-teens in Q2, indicating strong underlying demand despite near-term customer project timing headwinds.

auto_awesomeAnalysis · DHR · Industrial Applications And Services

Danaher delivered a strong Q2, with net earnings surging 60% to $870 million and adjusted EPS of $1.94 beating expectations. Core revenue grew 3%, driven by a rebound in Life Sciences and mid-teens bioprocessing order growth. Management raised full-year adjusted EPS guidance to $8.45–$8.60, signaling confidence in sustained momentum. The pending StatLab acquisition adds a high-growth, recurring-revenue asset to the diagnostics portfolio. Against a backdrop of recent debt-fueled M&A, these results demonstrate effective integration and operational execution, supporting the premium valuation.